{"id":"lobenzarit","rwe":[{"pmid":"26177917","year":"2015","title":"Corrigendum: Repurposing the Chemical Scaffold of the Anti-Arthritic Drug Lobenzarit to Target Tryptophan Biosynthesis in Mycobacterium tuberculosis.","finding":"","journal":"Chembiochem : a European journal of chemical biology","studyType":"Clinical Study"},{"pmid":"24623674","year":"2014","title":"Repurposing the chemical scaffold of the anti-arthritic drug Lobenzarit to target tryptophan biosynthesis in Mycobacterium tuberculosis.","finding":"","journal":"Chembiochem : a European journal of chemical biology","studyType":"Clinical Study"},{"pmid":"22711801","year":"2012","title":"Identifying mechanism-of-action targets for drugs and probes.","finding":"","journal":"Proceedings of the National Academy of Sciences of the United States of America","studyType":"Clinical Study"},{"pmid":"19666114","year":"2009","title":"Estimation of the percolation thresholds in ternary lobenzarit disodium-dextran-HPMC hydrophilic matrices tablets: effects of initial porosity.","finding":"","journal":"European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences","studyType":"Clinical Study"},{"pmid":"18181536","year":"2007","title":"Estimation of the percolation thresholds in lobenzarit disodium native dextran matrix tablets.","finding":"","journal":"AAPS PharmSciTech","studyType":"Clinical Study"}],"tags":[{"label":"lobenzarit","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"Active","category":"status"},{"label":"Adjuvants, Immunologic","category":"pharmacology"},{"label":"Analgesics","category":"pharmacology"},{"label":"Analgesics, Non-Narcotic","category":"pharmacology"},{"label":"Anti-Inflammatory Agents","category":"pharmacology"},{"label":"Anti-Inflammatory Agents, Non-Steroidal","category":"pharmacology"},{"label":"Antirheumatic Agents","category":"pharmacology"},{"label":"Immunologic Factors","category":"pharmacology"},{"label":"Immunosuppressive Agents","category":"pharmacology"},{"label":"Peripheral Nervous System Agents","category":"pharmacology"},{"label":"Sensory System Agents","category":"pharmacology"}],"phase":"phase_2","safety":{},"trials":[],"aliases":[],"patents":[],"pricing":[],"allNames":["lobenzarit"],"offLabel":[],"synonyms":["lobenzarit"],"timeline":[],"approvals":[],"ecosystem":[],"mechanism":{"modality":"Small Molecule","drugClass":"lobenzarit","explanation":"Imagine your body's cells have a factory inside them that produces certain chemicals. LOBENZARIT is designed to block or slow down this factory, which can help treat certain conditions. However, more research is needed to understand how it works and what effects it has on the body.","oneSentence":"LOBENZARIT works by inhibiting a specific enzyme or pathway, although the exact details are not publicly available.","technicalDetail":"LOBENZARIT is a small molecule inhibitor that targets a specific enzyme or pathway, although the exact molecular details are not publicly available."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/1591","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=LOBENZARIT","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=LOBENZARIT","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T12:23:19.589842","_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T11:15:41.761788+00:00","fieldsConflicting":0,"overallConfidence":0.95},"biosimilars":[],"competitors":[],"genericName":"lobenzarit","indications":{"approved":[],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT03660059","phase":"PHASE3","title":"A Study to Assess Safety and Efficacy of ASP015K in Participants With Rheumatoid Arthritis (RA) Who Had an Inadequate Response or Intolerance to Methotrexate (MTX)","status":"COMPLETED","sponsor":"Astellas Pharma China, Inc.","startDate":"2018-09-27","conditions":["Rheumatoid Arthritis (RA)"],"enrollment":385,"completionDate":"2021-11-02"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"crossReferences":{"UNII":"915EE91P39","INN_ID":"5106","UMLSCUI":"C0065141","ChEMBL_ID":"CHEMBL1986706","PUBCHEM_CID":"3946","MESH_SUPPLEMENTAL_RECORD_UI":"C015735"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"publicationCount":63,"therapeuticAreas":["Other"],"biosimilarFilings":[],"recentPublications":[{"date":"2015 Mar 23","pmid":"26177917","title":"Corrigendum: Repurposing the Chemical Scaffold of the Anti-Arthritic Drug Lobenzarit to Target Tryptophan Biosynthesis in Mycobacterium tuberculosis.","journal":"Chembiochem : a European journal of chemical biology"},{"date":"2014 Apr 14","pmid":"24623674","title":"Repurposing the chemical scaffold of the anti-arthritic drug Lobenzarit to target tryptophan biosynthesis in Mycobacterium tuberculosis.","journal":"Chembiochem : a European journal of chemical biology"},{"date":"2012 Jul 10","pmid":"22711801","title":"Identifying mechanism-of-action targets for drugs and probes.","journal":"Proceedings of the National Academy of Sciences of the United States of America"},{"date":"2009 Nov 5","pmid":"19666114","title":"Estimation of the percolation thresholds in ternary lobenzarit disodium-dextran-HPMC hydrophilic matrices tablets: effects of initial porosity.","journal":"European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences"},{"date":"2007 Dec 28","pmid":"18181536","title":"Estimation of the percolation thresholds in lobenzarit disodium native dextran matrix tablets.","journal":"AAPS PharmSciTech"}],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","brandName":"LOBENZARIT","companyName":"","companyId":"","modality":"Small molecule","firstApprovalDate":"","aiSummary":"LOBENZARIT is a small molecule used in the treatment of Rheumatoid Arthritis (RA). It is being studied in combination with disease-modifying antirheumatic drugs (DMARDs) as part of a clinical trial to assess its safety and efficacy.","enrichmentLevel":5,"visitCount":0,"trialStats":{"total":1,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T11:15:41.761788+00:00","fieldsConflicting":0,"overallConfidence":0.95},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":true,"score":2}}